Services

Translational Science

NDA Advisory Board

Regulatory Affairs

Pharmaco-
vigilance

High-Stakes Meetings

Health Technology Assessment

Spotlight

Brexit Impact

Are you ready?

More

More Spotlight Videos

News

Meet the NDA experts in March

14th March 2019

March is a busy month for our NDA experts and there are plenty of opportunities to meet them and discuss. This month we are participating in several events across the globe. If you would like to book a time to speak with one of our experts, contact us! Brian Edwards Principal Consultant, Pharmacovigilance & Drug …

More

Interactions with Agencies During Drug Development

5th March 2019

Welcome to NDA’s free Breakfast seminar on Wednesday 20th March 08:30- 10:00 on Interactions with Agencies During Drug Development.

More

Design and optimisation of a quality target product profile for ATMPs

1st March 2019

NDAs Paula Salmikangas discusses how the Quality Target Product Profile (QTPP) can be put to best use when developing ATMP’s.

More

Rare Diseases and FDA Advisory Committees: Be the Experts in the Room

28th February 2019

NDAs Neelu Agrawal describes the unique challenges, along with key factors for success when preparing for an advisory committee for a rare disease.

More

Passionate about solutions for patients with rare diseases

27th February 2019

Rare Disease Day is NDA Groups’ opportunity to show that we care passionately about this work and about getting treatments to the patients affected and to promote the vital work that is going on in this space by so many passionate patients, physicians and scientists.

More

Immunogenicity for investigational biopharmaceutical products – Start with the goal in mind

20th February 2019

Welcome to NDA’s free Breakfast seminar in Munich, Germany, on Thursday 14th March 09:00- 10:30 on Immunogenicity for investigational biopharmaceutical products – Start with the goal in mind.

More

Effective presentation of immunogenicity related data in regulatory dossiers

NDAs Paul Chamberlain provides practical advice about how to present immunogenicity-related information in regulatory dossiers in the latest publication of Bioanalysis.

More
More News
We have helped over 2,000 clients achieve success in the past
We have helped over 2,000 clients achieve success in the past

The leader in FDA Advisory Committee meeting preparation

“For innovative life science companies, NDA and PharmApprove are the best partners to help prepare to win at FDA Advisory Committees. Our pioneering approach — refined over 16 years experience and 150-plus projects — has helped more than 80 clients achieve success at these high-profile, high-stakes hearings.

NDA Intelligence

Subscribe to the latest intelligence from the true thought leaders in the field and access it at any time.

Members

A Career with NDA

Join NDA and get the chance to work with some of the leading minds in regulatory affairs, pharmacovigilance, health technology assessment and scientific communications on a variety of projects, clients and geographies.

Join NDA and get the chance to work with some of the leading minds in regulatory affairs, pharmacovigilance,

Why work at NDA?

Our Locations

NDA Sweden

NDA Group AB
Johanneslundsv. 2
S-194 61 Upplands Väsby
Sweden

T. +46 (0)8 590 778 00
E. stockholm@ndareg.com

NDA France

7, rue Jobbé Duval,
75015 Paris,
France

T. +33 983 981 942
E. paris@ndareg.com

NDA Germany

Neumarkter Straße 18
D-81673 München
Germany

T. +49 (0)89 3585 4000
E. munich@ndareg.com

NDA Switzerland

Rigistrasse 5
8703 Erlenbach
Switzerland

T. +41 (0)78 951 9929
E. zurich@ndareg.com

NDA UK

Grove House
Guildford Road
Leatherhead,
Surrey KT22 9DF
United Kingdom

T. +44 (0) 1372 860 610
E. london@ndareg.com

NDA USA Massachusetts

NDA Regulatory Development Inc.
1 Broadway, 14th floor
Cambridge, MA 02142
United States

T. +1 609 583 1990
E. usa@ndareg.com

NDA USA New Jersey

PharmApprove
200 Princeton South Corporate Center,
Suite 340
Ewing, NJ 08628
United States

T. +1 609 583 1990
E. usa@ndareg.com